{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:55:10Z","timestamp":1783979710186,"version":"3.55.0"},"reference-count":39,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T00:00:00Z","timestamp":1627171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>There is still limited data available from real-world experience studies on the pangenotypic regimens in patients with genotype (GT) 3 hepatitis C virus (HCV) infection and liver cirrhosis. The current study aimed to evaluate the efficacy and safety of pangenotypic regimens in this difficult-to-treat population. A total of 236 patients with mean age 52.3 \u00b1 11.3 years and male predominance (72%) selected from EpiTer-2 database were included in the analysis; 72% of them were treatment-na\u00efve. The majority of patients (55%) received the combination of sofosbuvir\/velpatasvir (SOF\/VEL), 71 without and 58 with ribavirin (RBV), whereas the remaining 107 individuals were assigned to glecaprevir\/pibrentasvir (GLE\/PIB). The effectiveness of the treatment following GLE\/PIB and SOF\/VEL regimens (96% and 93%) was higher compared to SOF\/VEL + RBV option (79%). The univariate analysis demonstrated the significantly lower sustained virologic response in males, in patients with baseline HCV RNA \u2265 1,000,000 IU\/mL, and among those who failed previous DAA-based therapy. The multivariate logistic regression analysis recognized only the male gender and presence of ascites at baseline as the independent factors of non-response to treatment. It should be emphasized that despite the availability of pangenotypic, strong therapeutic options, GT3 infected patients with cirrhosis still remain difficult-to-treat, especially those with hepatic impairment and DAA-experienced.<\/jats:p>","DOI":"10.3390\/jcm10153280","type":"journal-article","created":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T22:06:21Z","timestamp":1627250781000},"page":"3280","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0938-1084","authenticated-orcid":false,"given":"Dorota","family":"Zar\u0119bska-Michaluk","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Jan Kochanowski University, 25-317 Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Jaroszewicz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Parfieniuk-Kowerda","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Bia\u0142ystok, 15-540 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5406-4603","authenticated-orcid":false,"given":"Ewa","family":"Janczewska","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Faculty of Health Sciences in Bytom, Medical University of Silesia, 41-902 Bytom, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Dybowska","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Collegium Medicum, Nicolaus Copernicus University, 87-030 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6044-0425","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Paw\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Collegium Medicum, Nicolaus Copernicus University, 87-030 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Halota","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Collegium Medicum, Nicolaus Copernicus University, 87-030 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u0142odzimierz","family":"Mazur","sequence":"additional","affiliation":[{"name":"Clinical Department of Infectious Diseases, Medical University of Silesia in Katowice, 41-500 Chorz\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Lorenc","sequence":"additional","affiliation":[{"name":"Pomeranian Center of Infectious Diseases, Medical University Gda\u0144sk, 80-214 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Janocha-Litwin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University Wroc\u0142aw, 50-367 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University Wroc\u0142aw, 50-367 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-4881","authenticated-orcid":false,"given":"Anna","family":"Piekarska","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of \u0141\u00f3d\u017a, 90-419 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Berak","sequence":"additional","affiliation":[{"name":"Hospital for Infectious Diseases in Warszawa, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Klapaczy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hepatology, Central Clinical Hospital of the Ministry of Internal Affairs and Administration, 00-241 Warszawa, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"St\u0119pie\u0144","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Jan Kochanowski University, 25-317 Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sobala-Szczygie\u0142","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Citko","sequence":"additional","affiliation":[{"name":"Medical Practice of Infections, Regional Hospital, 10-561 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Socha","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, 71-455 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-5432","authenticated-orcid":false,"given":"Magdalena","family":"Tudrujek-Zdunek","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Tomasiewicz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Medical University of Lublin, 20-059 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Sitko","sequence":"additional","affiliation":[{"name":"Department of Infectious and Tropical Diseases, Jagiellonian University, 31-088 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Dobracka","sequence":"additional","affiliation":[{"name":"MED-FIX, 53-522 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3821-6854","authenticated-orcid":false,"given":"Rafa\u0142","family":"Krygier","sequence":"additional","affiliation":[{"name":"Outpatients Hepatology Department, State University of Applied Sciences, 62-510 Konin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Bia\u0142kowska-Warzecha","sequence":"additional","affiliation":[{"name":"Department of Infectious and Liver Diseases, Medical University \u0141\u00f3d\u017a, 90-419 \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Laurans","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, 71-455 Szczecin, Poland"},{"name":"Multidisciplinary Regional Hospital, 66-418 Gorz\u00f3w Wielkopolski, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-1635","authenticated-orcid":false,"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Bia\u0142ystok, 15-540 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,25]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2016). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021, World Health Organization. Available online: http:\/\/apps.who.int\/iris\/bitstream\/10665\/246177\/1\/WHO-HIV-2016.06-eng.pdf?ua=1."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.27095","article-title":"HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV","volume":"60","author":"Kanwal","year":"2014","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1111\/j.1365-2893.2011.01441.x","article-title":"HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis","volume":"18","author":"Nkontchou","year":"2011","journal-title":"J. Viral. Hepat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5114\/ceh.2016.63871","article-title":"Prevalence of HCV genotypes in Poland\u2014The EpiTer study","volume":"2","author":"Flisiak","year":"2016","journal-title":"Clin. Exp. Hepatol"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5114\/ceh.2016.63870","article-title":"Efficacy of HCV treatment in Poland at the turn of the interferon era\u2014The EpiTer study","volume":"2","author":"Flisiak","year":"2016","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection","volume":"149","author":"Foster","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3851\/IMP3278","article-title":"Daclatasvir and sofosbuvir with ribavirin for 24 wk in chronic hepatitis C genotype-3-infected patients with cirrhosis: A Phase III study (ALLY-3C)","volume":"24","author":"Poordad","year":"2019","journal-title":"Antivir. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/jir.2017.0113","article-title":"Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?","volume":"38","author":"Flisiak","year":"2018","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_11","unstructured":"European Association for the Study of the Liver (2020). Clinical Practice Guidelines Panel: Chair, EASL Governing Board representative, Panel members. EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5114\/ceh.2020.98606","article-title":"Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020","volume":"6","author":"Halota","year":"2020","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3748\/wjg.v27.i11.1006","article-title":"Genotype 3-hepatitis C virus\u2019 last line of defense","volume":"27","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.7326\/M15-1014","article-title":"Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial","volume":"163","author":"Pianko","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","article-title":"Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis","volume":"155","author":"Esteban","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mangia, A., Cenderello, G., Copetti, M., Verucchi, G., Piazzolla, V., Lorusso, C., Santoro, R., Squillante, M.M., Orlandini, A., and Minisini, R. (2019). SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF\/VEL without Ribavirin: A Nation-Wide Cohort Study. Cells, 8.","DOI":"10.3390\/cells8040313"},{"key":"ref_19","first-page":"360A","article-title":"Effectiveness of Sofosbuvir\/Velpatasvir for 12 weeks in HCV genotype 3 patients with compensated cirrhosis in clinical practice cohorts from around the world","volume":"68","author":"Fagiuoli","year":"2018","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhep.2018.09.018","article-title":"Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir\/sofosbuvir in hepatitis C genotype 2 and 3","volume":"70","author":"Belperio","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_21","unstructured":"(2021, June 13). Epclusa Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epclusa#product-information-section."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mangia, A., Losappio, R., Cenderello, G., Potenza, D., Mazzola, M., De Stefano, G., Terreni, N., Copetti, M., Minerva, N., and Piazzola, V. (2018). Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis\/cirrhosis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0200568"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"550205","DOI":"10.3389\/fphar.2020.550205","article-title":"Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir\/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes from Pakistan","volume":"11","author":"Mushtaq","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5604\/01.3001.0012.7931","article-title":"Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done","volume":"18","author":"Llerena","year":"2019","journal-title":"Ann. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/hep.29256","article-title":"Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen","volume":"66","author":"Gane","year":"2017","journal-title":"Hepatology"},{"key":"ref_26","unstructured":"European Medicines Agency (2021, June 13). EMA\/332999\/2020. Maviret: Procedural Steps Taken and Scientific Information after the Authorization, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/maviret-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 wk in treatment-na\u00efve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: A partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2018","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jvh.13038","article-title":"Glecaprevir\/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2\/3 analysis","volume":"26","author":"Flamm","year":"2019","journal-title":"J. Viral. Hepat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: Data from the German Hepatitis C-Registry","volume":"49","author":"Berg","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"NAVIGATORE-Lombardia Study Group. Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C","volume":"70","author":"Pasulo","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/jgh.14874","article-title":"Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection","volume":"35","author":"Toyoda","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s12325-020-01301-5","article-title":"Effectiveness of 8-Week Glecaprevir\/Pibrentasvir for Treatment-Na\u00efve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection","volume":"37","author":"Flamm","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1007\/s12325-020-01449-0","article-title":"Real-World Clinical Practice Use of 8-Week Glecaprevir\/Pibrentasvir in Treatment-Na\u00efve Patients with Compensated Cirrhosis","volume":"37","author":"Lampertico","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_35","first-page":"417A","article-title":"Real-world effectiveness of glecaprevir\/pibrentasvir in 1,941 patients with hepatitis C genotypes 1 through 4","volume":"68","author":"Belperio","year":"2018","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zar\u0119bska-Michaluk, D., Jaroszewicz, J., Pabjan, P., \u0141api\u0144ski, T.W., Mazur, W., Krygier, R., Dybowska, D., Halota, W., Paw\u0142owska, M., and Janczewska, E. (2020). Is an 8-week regimen of glecaprevir\/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?. J. Gastroenterol. Hepatol.","DOI":"10.1111\/jgh.15337"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1136\/ejhpharm-2019-002060","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir \u00b1 ribavirin vs. glecaprevir\/pibrentasvir in genotype 3 hepatitis C virus infected patients","volume":"27","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/liv.14386","article-title":"Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort","volume":"40","author":"Soria","year":"2020","journal-title":"Liver Int."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sarrazin, C. (2021). Treatment failure with DAA therapy: Importance of resistance. J. Hepatol.","DOI":"10.1016\/j.jhep.2021.03.004"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/15\/3280\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:34:42Z","timestamp":1760164482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/15\/3280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,25]]},"references-count":39,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["jcm10153280"],"URL":"https:\/\/doi.org\/10.3390\/jcm10153280","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,25]]}}}